Related references
Note: Only part of the references are listed.Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
Ramona Wullenkord et al.
ANNALS OF HEMATOLOGY (2021)
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
Talha Badar et al.
CANCER (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database
Elias Jabbour et al.
LEUKEMIA & LYMPHOMA (2020)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Emanuele Zucca et al.
BLOOD (2019)
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)
Othman Al-Sawaf et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy
Bruno Emond et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
David Marks et al.
CANCER MEDICINE (2019)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Meaningful endpoints for therapies approved for hematologic malignancies
B. Douglas Smith et al.
CANCER (2017)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
Nicola Goekbuget et al.
HAEMATOLOGICA (2016)
Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL
Shannon L. Maude et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Boris Shor et al.
MOLECULAR IMMUNOLOGY (2015)
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells
Clive S. Zent et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
Lisa Kujawski et al.
BLOOD (2008)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Share Paper
